Want to see SE:ATORX full AI Analyst Report?
Top Page
Alligator Bioscience AB
(ATORX)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.04
▼(-18.00% Downside)
Action:Upgraded
Date:07/28/26
The score is primarily weighed down by weak financial performance: very limited and declining revenue, persistent losses, and significant negative free cash flow that suggests continued financing needs. Technicals add further downside risk as the stock trades well below all major moving averages. Valuation provides limited support because the negative P/E makes earnings-based valuation unreliable and no dividend yield is available.
Positive Factors
Improved balance sheet and lower leverage
Lower leverage and rebuilt positive equity materially improve financial flexibility for a clinical-stage biotech. This reduces insolvency risk, supports continued R&D funding or partner negotiations, and makes future financing or licensing deals easier to structure over the next several quarters.
Negative Factors
Large negative operating and free cash flow
Sustained, large cash burn implies ongoing external financing or dilutive capital raises. That constrains strategic optionality, pressures management to prioritize near-term financing over long-term R&D choices, and elevates execution risk if funding conditions tighten over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet and lower leverage
Lower leverage and rebuilt positive equity materially improve financial flexibility for a clinical-stage biotech. This reduces insolvency risk, supports continued R&D funding or partner negotiations, and makes future financing or licensing deals easier to structure over the next several quarters.
Read all positive factors
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr22.88M
Dividend YieldN/A
Average Volume (3M)1.75M
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth-98.99%
EPS Growth86.37%
CountrySE
Employees11
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.07
Shares Outstanding534,516,970
10 Day Avg. Volume1,169,449
30 Day Avg. Volume1,745,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Alligator Bioscience AB Business Overview & Revenue Model
Company Description
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its ...
How the Company Makes Money
Alligator Bioscience’s business model is typical of clinical-stage biotechnology companies: it develops proprietary drug candidates and seeks to monetize them primarily through partnering rather than through product sales (the company is not known...
Alligator Bioscience AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 603.00K | 514.00K | 57.77M | 58.11M | 35.70M | 12.94M |
| Gross Profit | -49.16M | -54.82M | 57.77M | 58.11M | -112.03M | -74.04M |
| EBITDA | -43.74M | -121.98M | -165.47M | -237.61M | -180.99M | -130.39M |
| Net Income | -41.56M | -51.35M | -233.89M | -248.59M | -193.40M | -141.74M |
Balance Sheet | ||||||
| Total Assets | 95.02M | 110.60M | 104.34M | 118.45M | 169.58M | 333.20M |
| Cash, Cash Equivalents and Short-Term Investments | 32.98M | 62.20M | 64.31M | 66.12M | 97.31M | 278.15M |
| Total Debt | 32.38M | 43.15M | 43.57M | 16.10M | 24.50M | 9.74M |
| Total Liabilities | 53.74M | 103.74M | 234.93M | 106.59M | 80.53M | 50.93M |
| Stockholders Equity | 41.28M | 6.86M | -130.59M | 11.86M | 89.05M | 282.27M |
Cash Flow | ||||||
| Free Cash Flow | -137.83M | -157.45M | -212.43M | -191.74M | -173.05M | -127.08M |
| Operating Cash Flow | -137.83M | -155.99M | -212.43M | -189.28M | -172.61M | -127.03M |
| Investing Cash Flow | 0.00 | 2.21M | 0.00 | -2.46M | -440.00K | -45.00K |
| Financing Cash Flow | 142.17M | 152.59M | 211.27M | 161.56M | -7.83M | 301.80M |
Alligator Bioscience AB Technical Analysis
Negative
0.05
Price Trends
0.16
Negative
0.19
Negative
0.26
Negative
Market Momentum
-0.04
Positive
17.66
Positive
12.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.16, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 17.66 is Positive, neither overbought nor oversold. The STOCH value of 12.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ATORX.
Alligator Bioscience AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | kr235.06M | -4.46 | -19.89% | ― | -100.00% | 11.65% | |
50 Neutral | kr44.88M | -1.72 | -335.50% | ― | ― | -28.21% | |
49 Neutral | kr142.32M | -2.61 | -80.87% | ― | 7.80% | 42.81% | |
48 Neutral | kr145.97M | 1.64 | 47.40% | ― | 57.22% | ― | |
44 Neutral | kr136.02M | -224.35 | -117.83% | ― | ― | 49.74% | |
41 Neutral | kr22.88M | -0.04 | -3992.70% | ― | -98.99% | 86.37% |
* General Sector Average
SE:ATORX
Alligator Bioscience AB
0.04
-1.40
-97.09%
SE:ALZ
Alzinova AB
1.03
-0.27
-20.68%
SE:NICA
Nanologica AB
0.46
-1.09
-70.31%
SE:MODTX
Modus Therapeutics Holding AB
0.39
-0.72
-65.00%
SE:ACTI
Active Biotech AB
5.37
-9.25
-63.26%
SE:NXTCL
NextCell Pharma AB
1.04
-0.16
-13.09%
Alligator Bioscience AB Corporate Events
Alligator Bioscience Calls Extraordinary Meeting to Restructure Capital and Approve Rights Issue
Jul 23, 2026
Alligator Bioscience AB has called an extraordinary general meeting for 26 August 2026 in Lund, where shareholders will vote on a series of capital and governance measures. The agenda includes amendments to the Articles of Association, multiple de...
Alligator Bioscience Shifts Focus to HLX22 and Launches SEK 125.6 Million Rights Issue
Jul 23, 2026
Alligator Bioscience is discontinuing independent development of its lead drug candidate mitazalimab and shifting strategic focus to the HLX22 project, from which it seeks to preserve future royalty potential. The company also plans to wind down r...
Alligator Bioscience Backs Intratumoral Mitazalimab Study in Early Breast Cancer
Jul 2, 2026
Alligator Bioscience has reported the first patient dosed in an investigator-initiated clinical trial of intratumoral mitazalimab in early-stage breast cancer at an Ivy League institution in the United States. The study administers a single intrat...
Alligator Bioscience Sees Revenue Upside as HLX22 Global Phase 3 Reaches Key Milestone
Jun 8, 2026
Alligator Bioscience highlighted progress in a global Phase 3 trial of HLX22, an innovative anti-HER2 monoclonal antibody for gastric cancer developed by Shanghai Henlius Biotech under license from AbClon. The trial has now dosed its first patient...
Alligator Bioscience Sees Long-Term Revenue Potential in Henlius’ HLX22 Progress
May 22, 2026
Alligator Bioscience has commented on an update from Shanghai Henlius Biotech regarding long-term follow-up data for HLX22, an anti-HER2 monoclonal antibody with orphan drug designation in the U.S. and EU for gastric cancer. Henlius reported that ...
Alligator Bioscience AGM Backs Loss Carryforward and Expands Capital-Raising Mandate
May 6, 2026
Alligator Bioscience AB’s annual general meeting adopted the 2025 accounts, confirmed that no dividend will be paid, and decided that the accumulated loss of SEK 83.3 million will be carried forward, underscoring the company’s continue...
Alligator Bioscience Advances Oncology Pipeline and Bolsters Capital Base in Q1 2026
May 5, 2026
Alligator Bioscience reported a steady first quarter of 2026 operationally, with no major events but continued progress across its oncology pipeline and platforms. The company highlighted new and updated mitazalimab data from the OPTIMIZE 1 study ...
Alligator Bioscience Sets May 5 Earnings Call as Lead Cancer Drug Nears Phase 3
Apr 28, 2026
Alligator Bioscience, a Lund-based biotech listed on Nasdaq Stockholm, specializes in tumor-directed antibody immuno-oncology therapies centered on CD40 receptor targeting, with lead asset mitazalimab advancing toward Phase 3 after strong survival...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.